Discordant Amyloid Status Diagnosis in Alzheimer's Disease.

Autores de IIS La Fe

• Lorena García Vallés

  Autor

• María Del Carmen Peña Bautista

  Autor

• Lourdes Álvarez Sánchez

  Autor

• Inés Ferrer Cairols

  Autor

• 

  Miguel Baquero Toledo

  Autor

• 

  María Consuelo Cháfer Pericás

  Autor

Grupos

• Grupo de Investigación en Enfermedad de Alzheimer (GINEA)

Abstract

Introduction: Early and accurate Alzheimer's disease (AD) diagnosis has evolved in recent years by the use of specific methods for detecting its histopathological features in concrete cases. Currently, biomarkers in cerebrospinal fluid (CSF) and imaging techniques (amyloid PET) are the most used specific methods. However, some results between both methods are discrepant. Therefore, an evaluation of these discrepant cases is required. Objective: The aim of this work is to analyze the characteristics of cases showing discrepancies between methods for detecting amyloid pathology. Methodology: Patients from the Neurology Department of La Fe Hospital (n = 82) were diagnosed using both methods (CSF biomarkers and amyloid-PET). Statistical analyses were performed using logistic regression, and sex and age were included as covariables. Additionally, results of standard neuropsychological evaluations were taken into account in our analyses. Results: The comparison between CSF biomarker (A beta 42) and amyloid PET results showed that around 18% of cases were discrepant-mainly CFS-negative and PET-positive cases had CSF levels close to the cut-off point. In addition, a correlation between the episodic memory test and CSF biomarkers levels was observed. However, the same results were not obtained for other neuropsychological domains. In general, CSF- and PET-discrepant cases showed altered episodic memory in around 66% of cases, while 33% showed normal performance. Conclusions: In common clinical practice at tertiary memory centers, result discrepancies between tests of amyloid status are far more common than expected. However, episodic memory tests remain an important support method for AD diagnosis, especially in cases with discrepant results between amyloid PET and CSF biomarkers.

Keywords

• cerebrospinal fluid sample; amyloid PET; Alzheimer's disease; diagnosis; neuropsychology